Estrogenic or antiestrogenic therapies for multiple myeloma?
2007

Estrogenic or antiestrogenic therapies for multiple myeloma?

publication Evidence: moderate

Author Information

Author(s): Sola Brigitte, Renoir Jack-Michel

Primary Institution: Université de Caen, Caen, France

Hypothesis

Can estrogenic and antiestrogenic compounds be effective treatments for multiple myeloma?

Conclusion

Estrogenic and antiestrogenic compounds can inhibit the growth of multiple myeloma cells and may provide a new therapeutic strategy.

Supporting Evidence

  • Estrogenic compounds inhibit cell proliferation in multiple myeloma cells.
  • These compounds induce apoptosis in drug-resistant multiple myeloma cells.
  • Estrogenic therapies can enhance the effects of conventional drugs.
  • 2-methoxyestradiol has shown antiangiogenic properties in xenograft models.

Takeaway

Some medicines that act like estrogen can help fight a type of blood cancer called multiple myeloma by stopping the cancer cells from growing.

Methodology

The review discusses preclinical studies of 2-methoxyestradiol, SERDs, and SERMs in multiple myeloma.

Limitations

The review is based on preclinical studies, and clinical efficacy in patients is yet to be established.

Digital Object Identifier (DOI)

10.1186/1476-4598-6-59

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication